OpGen (OTC:OPGN) Stock Crosses Above Fifty Day Moving Average - What's Next?
OpGen's stock price surged above its 50-day moving average, trading as high as $5.04, marking an 80% increase. Despite this rise, analysts suggest other stocks may be better investments, as OpGen holds a 'Hold' rating. The company specializes in molecular microbiology solutions.
OpGen, Inc. (OTC:OPGN - Get Free Report)'s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.10 and traded as high as $5.04. OpGen shares last traded at $5.04, with a volume of 15,783 shares trading hands.
OpGen Trading Up 80.0%
The company has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $3.19. The company has a market cap of $50.76 million, a PE ratio of -0.90 and a beta of -1.77.
About OpGen
(Get Free Report)OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Read More
- Five stocks we like better than OpGen
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- onsemi Places a $6 Billion Bet on Its Own Stock
- Bank Stocks - Best Bank Stocks to Invest In
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- End the Year Strong With These 3 Comeback Champions
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in OpGen Right Now?
Before you consider OpGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OpGen wasn't on the list.
While OpGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
